Sym023 is a mAb that binds TIM3 and induces activation of immune cells.
The Phase 1 trials are studies to test Sym021, Sym022 and Sym023 in humans. The primary purpose of these trials is to determine if Sym021, Sym022 and Sym023 are safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Clinical development of Sym023
Today, Sym023 (targeting TIM3) is being investigated in Phase 1 trials in combination with Sym021 (targeting PD1) and as single antibody. TIM3 and PD1 are immune checkpoints playing important roles in regulating immune responses, including the body’s immune response to tumor cells.
Identifying I/O targets
Symphogen has proven its ability to deliver unique antibodies on aggressive timelines as exemplified with our filing of three INDs in six months – Sym021, Sym022 and Sym023. Such an exceptional achievement is made possible by the unique way we run projects. Developability assessment is an integrated part of
the lead selection process, which means that potential critical features of the lead candidates are taken into consideration very early in the development path.